Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC-100 and Propranolol for Stem Cell Mobilization in Multiple Myeloma
NCT05561751Phase 2Completed
- Sponsor
- GPCR Therapeutics
- Start
- Feb 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of burixafor in multiple myeloma (MM) (2 arms), sponsored by GPCR Therapeutics. Primary endpoint: Proportion of patients that achieve >=2 x 10^6 CD34+ cells/kg in 2 leukapheresis sessions at 2 days. Started Feb 2023; status: completed.
02
Drugs
burixafor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05561751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561751.